Concurrent therapy with other Investigational Products. Patient has history of allergy to any oily drug products Treatment with any investigational products within days before the first dose of protocol-indicated treatment Treatment with any investigational products within days prior to study registration Treatment with any investigational products within weeks before administration of the first dose of the study drugs. Treatment with any investigational products within days before randomization. Treatment with any investigational products within days before the first dose of study drug Treatment with any investigational products within weeks before the first dose of study drug. Known prior or suspected hypersensitivity to investigational products Treatment with any investigational products within days before the first dose of any study drug Previous treatment with venetoclax and/or current participation in any other research study with investigational products. Concurrent therapy with other investigational products Treatment with any investigational products within days before the first dose of any study drug Currently using aluminum-containing antacid products Confirmed availability of production capacities for the patient's ACTolog products. Previous treatment with investigational gene or cell therapy medicine products Treatment with any investigational products within days before the first dose of study drug Treatment with any investigational products within weeks before the first dose of study drug Consumption or use of any Noni or Noni-containing products User of herbal products Treatment with any investigational products within weeks before the first dose of study drug History of allergy or untoward reaction to yeast-based products (any hypersensitivity to yeast-based products will be excluded) Within the month immediately preceding the screening visit, use of any form of tobacco products other than cigarettes on or more days within a week if the individual refuses to refrain from such tobacco use during the course of the study History of hypersensitivity reactions to products containing irinotecan (irinotecan), topotecan or other topoisomerase inhibitors, gadolinium contrast agents or lipid products Previous treatment with any substrate of CYPB enzyme < days prior to initiation of investigational products Treatment with any investigational products within weeks before the first dose of any study drug Patients taking any clay products Concurrent use of tobacco products (other than cigarettes) or nicotine products. Treatment with any investigational products within days prior to study registration Treatment with other investigational products within the last months prior to entry into this study Individuals who are willing to not start any new products OTC or prescription treatments for Paronychia and discontinue any treatment the investigator feels may interfere with the evaluation of the test products Treatment with any anti leukemic/anti MDS therapies (eg, lenalidomide, cytarabine, anthracyclines, purine analogs) or with any investigational products within days before the first dose of any study drug. Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products Not be allergic to tomatoes or tomato products Any major surgery =< days prior to the initiation of investigational products Treatment with any investigational products within days before the first dose of the study drug regimen. Received radiation therapy =< days prior to initiation of investigational products Known prior or suspected hypersensitivity to investigational products. Treatment with any investigational products within weeks before the first dose of any study drug Treatment with any investigational products within days before the first dose of study drug Treatment with any investigational products within days before the first dose of the study drug regimen Patients who have used tobacco or nicotine products or medications within the last three months given their significant effect on erlotinib drug levels Treatment with chemotherapy, radiotherapy, surgery, blood products, or an investigational agent within weeks of trial enrolment Therapy with herbal products known to effect PSA, or estrogen within days prior to the start of study medication Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules At least weeks since the last chemotherapy, radiation therapy, immunotherapy or any investigational products Treatment with any anticancer therapy or any investigational products within weeks before the first dose of study drug. Treatment with any systemic antineoplastic therapy or investigational products within days before the first dose of study treatment. Treatment with any investigational products days prior to treatment PART I: Participants who smoke tobacco products will not be allowed to participate PART II: Those who smoke tobacco products will not be allowed to participate Treatment with any investigational products Exposure to more than investigational medicinal products within months prior to the first dose of study treatment Subjects must not be currently using other tobacco or nicotine products. Investigational products or therapy other than ASP Therapy with any investigational products within days before the first dose of study drug Regular use of tobacco products other than cigarettes Willingness to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment Extensive history of using smokeless tobacco products or marijuana defined as daily use >= years Use of any estrogen containing medications, products, or preparations Abstention from meat and other animal products Willing to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment Willing to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment Current use of tobacco/tobacco-containing products; Exclusive use of tobacco products other than cigarettes, such as (but not limited to) cigars, chew, snuff, pipe or electronic (e)-cigarettes (cigs). Not be allergic to tomato or tomato products Used other tobacco products (including e-cigarettes) more than days in the past month Willing to abstain from cannabis and other tobacco products during study procedures Within the month immediately preceding the screening visit, use of any form of tobacco products other than cigarettes, little cigars or cigarillos on or more days within a week if the individual refuses to refrain from such tobacco use during the course of the study Smoker or uses smokeless tobacco products Use of tobacco products other than cigarettes in past days Within the month immediately preceding the screening visit, use of any form of tobacco products other than cigarettes, little cigars or cigarillos on or more days within a week if the individual refuses to refrain from such tobacco use during the course of the study STUDY I: Former dual users who have quit both products Allergic to fish products Use of tobacco products other than cigarettes in past days Currently using nicotine replacement or other tobacco cessation products or intentionally abstaining from nicotine-containing products Hypersensitivity to potassium iodide or Lugols products Hypersensitivity to iodide products No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the dental/medical professional monitoring the study History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses; allergy to personal care/consumer products or their ingredients Received other investigational products or therapy in the days prior to study drug administration. Use of tobacco- or nicotine-containing products in excess of the equivalent of cigarettes per day Use in the past days of tobacco or nicotine products including e-cigarettes, other than regular cigarettes Current use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes) or use of these products within months of study registration Other tobacco use (e.g., combustible products, vapors, etc.) within the last months Regular use (e.g., greater than weekly) of tobacco products (including e-cigarettes) other than cigarettes Use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes) Subject has provided written informed consent to participate in the study\n (adolescents under the age of will be excluded because this project involves\n continued use of tobacco products and new tobacco products); Pregnant or breastfeeding (due to toxic effects from tobacco products).